URINARY-EXCRETION OF EPHEDRINE AFTER NASAL APPLICATION IN HEALTHY-VOLUNTEERS

被引:8
作者
LEFEBVRE, RA [1 ]
SURMONT, F [1 ]
BOUCKAERT, J [1 ]
MOERMAN, E [1 ]
机构
[1] STATE UNIV GHENT,SCH MED,INST PHYS EDUC,B-9000 GENT,BELGIUM
关键词
D O I
10.1111/j.2042-7158.1992.tb05492.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The urinary excretion of ephedrine after intranasal administration of the drug was studied in 8 healthy volunteers. Ephedrine (6 drops of a commercial 0.75% nasal ephedrine solution in each nasal cavity) was administered 4 times at intervals of 2 h (total amount applied equivalent to approximately 14 mg ephedrine), and urine was collected each hour for 10 h; the volunteers exercised on a bicycle ergometer at 50% of their VO2max over circle for 2 h after the last ephedrine application. Ephedrine was detected in all urine samples. The urinary ephedrine concentration ranged from 0.9 to 16.5-mu-g mL-1; the number of urine samples with an ephedrine concentration exceeding 5-mu-g mL-1 ranged from 1/10 (volunteer 2) to 9/10 (volunteers 1 and 3). The mean percentage of dose recovered within 10 h was 33% (range 23-50%). There was a weak but significant negative correlation between urinary pH and amount of ephedrine in the urine; exercise did not consistently influence the urinary amount. These results illustrate the systemic availability of ephedrine upon intranasal administration and show that the therapeutic use of a nasal ephedrine formulation by an athlete on the day of a competition can lead to a urinary ephedrine concentration above 5-mu-g mL-1, which is considered positive in current doping regulations of the International Union of Cyclists.
引用
收藏
页码:672 / 675
页数:4
相关论文
共 14 条
[1]   SENSITIVE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF PSEUDOEPHEDRINE IN PLASMA AND URINE [J].
BRENDEL, E ;
MEINEKE, I ;
HENNE, EM ;
ZSCHUNKE, M ;
DEMEY, C .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1988, 426 (02) :406-411
[2]  
BROGGINI M, 1991, METHOD FIND EXP CLIN, V13, P193
[3]  
Castenfors J, 1977, Ann N Y Acad Sci, V301, P151, DOI 10.1111/j.1749-6632.1977.tb38194.x
[4]  
DALMONTE A, 1988, OLYMPIC BOOK SPORTS, P109
[5]   INTRANASAL DRUG DELIVERY BY SPRAY AND DROPS [J].
HARDY, JG ;
LEE, SW ;
WILSON, CG .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1985, 37 (05) :294-297
[6]   NASAL ABSORPTION OF PROPRANOLOL IN HUMANS [J].
HUSSAIN, A ;
FOSTER, T ;
HIRAI, S ;
KASHIHARA, T ;
BATENHORST, R ;
JONES, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (10) :1240-1240
[7]  
PARR GD, 1983, PHARM INT, V4, P202
[8]   INTRANASAL DRUG DELIVERY - POTENTIAL ADVANTAGES AND LIMITATIONS FROM A CLINICAL PHARMACOKINETIC PERSPECTIVE [J].
PONTIROLI, AE ;
CALDERARA, A ;
POZZA, G .
CLINICAL PHARMACOKINETICS, 1989, 17 (05) :299-307
[9]   METABOLISM OF (-)-EPHEDRINE IN MAN [J].
SEVER, PS ;
DRING, LG ;
WILLIAMS, RT .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1975, 9 (2-3) :193-198
[10]   EFFECT OF EXERCISE ON DISPOSITION AND PHARMACOKINETICS OF DRUGS [J].
SOMANI, SM ;
GUPTA, SK ;
FRANK, S ;
CORDER, CN .
DRUG DEVELOPMENT RESEARCH, 1990, 20 (03) :251-275